Guardant Health
GH
#3559
Rank
NZ$4.98 B
Marketcap
$40.55
Share price
-1.18%
Change (1 day)
-12.26%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Guardant Health (GH) Fails to deliver data

Key failure to deliver metrics for Guardant Health :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Guardant Health (GH) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Guardant Health (GH) - since 2018

Volume in USD (price x number of shares), data since 2018

Guardant Health (GH) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024NZ$4.18 M-70.25%
2023NZ$14.08 M47.94%
2022NZ$9.51 M-97.95%
2021NZ$0.46 B195%
2020NZ$0.15 B-29.91%
2019NZ$0.22 B2130.55%
2018NZ$10.06 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
NZ$1.57 MNZ$18.04 M๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.5 MNZ$16.88 M๐Ÿ‡บ๐Ÿ‡ธ USA